Sfoglia per Afferenza Dipartimento di Medicina clinica, sanità pubblica, scienze della vita e dell'ambiente

Opzioni
Vai a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Mostrati risultati da 8.783 a 8.802 di 18.318
Titolo Data di pubblicazione Autore(i) File
Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction 1-gen-2005 Patti, G; Mega, S; Pasceri, V; Nusca, A; Giorgi, G; Zardi, Em; D'Ambrosio, A; Dobrina, A; Di Sciascio, G
Interleukin-1 receptor antagonist: A sensitive marker of instability in patients with coronary artery disease 1-gen-2002 Patti, G; D'Ambrosio, A; Dobrina, A; Dicuonzo, G; Giansante, C; Fiotti, N; Abbate, A; Guarnieri, G; Di Sciascio, G
Interleukin-18 in obese children and adolescents: new marker of inflammation and endothelial cell activation 1-gen-2007 De Simone, M; Iezzi, Ml; Desideri, Giovambattista; Ferri, Claudio; Raiola, G; Pellegrino, K; Pezone, I.
Interleukin-1beta specifically stimulates nitric oxide production in the hypothalamus 1-gen-1996 Brunetti, L; Volpe, ANNA RITA; Ragazzoni, E; Preziosi, P; Vacca, M.
Interleukin-1beta stimulates nitric oxide release from cultured rat hypothalamic cells in vitro 1-gen-1995 L., Brunetti; Volpe, ANNA RITA; E., Ragazzoni; P., Preziosi; M., Vacca
Interleukin-1beta-producing plasma cells in close contact with hepatocytes in patients with chronic active hepatitis 1-gen-1997 Hassan, G; Moreno, S; Massimi, Mara; DI BIAGIO, P; Stefanini, S.
. Interleukin-2 (IL-2) and 13-cis retinoic acid (RA) decrease vascular endothelial growth factor (VEGF) and prolong disease-free and overall survival in patients with non small cell lung cancer (NSCLC) responsive to chemotherapy. J Clin Oncol 2005: 23, 234s (supplement), abstract #3171. 1-gen-2005 Recchia, F; Saggio, G; Cesta, A; Candeloro, G; Nuzzo, A; Lombardo, M; Rea, Silvio
Interleukin-2 (IL-2) and 13-cis retinoic acid (RA) decrease vascular endothelial growth factor (VEGF) and prolong clinical benefit in patients with advanced solid tumors showing a partial response (PR) or stable disease (SD) to chemotherapy. J Clin Oncol 2005: 2, 27s (supplement). 1-gen-2005 Saggio, G; Cesta, A; Amiconi, G; Di Blasio, A; Candeloro, G; Alesse, E; Rea, Silvio
Interleukin-2 (IL-2) and 13-cis retinoic acid (RA) dicrease serum vascular endothelial growth factor (VEGF) of patients with platinum sensitive, advanced ovarian cancer (AOC) 1-gen-2005 Recchia, F; Cesta, A; Candeloro, G; Saggio, G; Nuzzo, A; Lalli, A; Lombardo, M; Carta, Gaspare; Rea, S.
Interleukin-2 (IL-2) and 13-cis retinoic acid (RA) prolong disease- free and overall survival in recurrent ovarian cancer (ROC).Annals of Oncology, 2004, 15: 131, abstract # 491P. 1-gen-2004 F., Recchia; G., Saggio; A., Cesta; A., Nuzzo; Carta, Gaspare; Rea, Silvio
Interleukin-2 (IL-2) and 13-cis retinoic acid (RA) prolong disease-free and overall survival in recurrent ovarian cancer (ROC) 1-gen-2004 Recchia, F; Saggio, G; Cesta, A; Nuzzo, A; Carta, Gaspare; Rea, S.
Interleukin-2 (IL-2) with 13-cis retinoic acid (RA) is more effective than IL-2 alone, as maintenance therapy in advanced cancer responsive to chemotherapy. Final result of a phase-II randomized trial. Proc Am Ass Cancer Res 2004: 45;1082. Abstract #4684. 1-gen-2004 F., Recchia; A., Cesta; G., Saggio; P., Alesse; R., Gallo; Rea, Silvio
Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer 1-gen-2005 Recchia, F; Saggio, G; Cesta, A; Candeloro, G; Nuzzo, A; Lombardo, M; Carta, Gaspare; Rea, Silvio
Interleukin-2 and 13-cis retinoic acid in the treatment ofMinimal residual disease. A phase II study. 1-gen-2002 F., Recchia; S., DE FILIPPIS; M., Rosselli; G., Saggio; L., Fumagalli; Rea, Silvio
Interleukin-2 and 13-cis retinoic acid prevent angiogenic switch in patients responsive to chemotherapy. Anticancer research. 2004: 24: 3609, abstract # 420. 1-gen-2004 F., Recchia; A., Cesta; G., Saggio; G., Candeloro; P., Alesse; R., Gallo; Rea, Silvio
Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro 1-gen-2000 Porta, C.; Danova, M.; Orengo, A. M.; Ferrini, S.; Moroni, M.; Gaggero, A.; Libener, R.; Betta, P. G.; Ferrari, S.; Procopio, A.; Strizzi, L.; Mutti, L.
Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-g production 1-gen-1999 Cifone, MARIA GRAZIA; S., D'Alo'; R., Parroni; D., Millimaggi; L., Biordi; S., Martinotti; A., Santoni
Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer 1-gen-2015 Airoldi, I.; Tupone, M. G.; Esposito, S.; Russo, M. V.; Barbarito, G.; Cipollone, G.; Di Carlo, E.
Interleukin-33 serum levels in postmenopausal women with osteoporosis 1-gen-2019 Ginaldi, Lia; DE MARTINIS, MASSIMO MARIA MARCELLO; Saitta, Salvatore; Sirufo, MARIA MADDALENA; Mannucci, Carmen; Casciaro, Marco; Ciccarelli, Fedra; Gangemi, Sebastiano
Interleukin7 engineered mesenchymal cells: in vitro effects on naive T cell population 1-gen-2006 Sportoletti, P; DEL PAPA, B; DE IOANNI, M; Moretti, L; Bonifacio, E; Lanterna, V; Bell, As; Fettucciari, K; Carnevali, E; Zei, T; Falzetti, F; Martelli, Mf; Tabilio, A; DI IANNI, Mauro
Mostrati risultati da 8.783 a 8.802 di 18.318
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile